博傑股份(002975.SZ):發行可轉債網上中籤率為0.00069%
格隆匯11月17日丨博傑股份(002975.SZ)公佈公開發行可轉換公司債券網上發行中籤率及優先配售結果公吿,原股東共優先配售博傑轉債4,545,481張,共計4.545億元,佔本次發行總量的86.42%。
本次發行最終確定的網上向社會公眾投資者發行的博傑轉債為7145.10萬元(714,510張),佔本次發行總量的13.58%。
根據深交所提供的網上申購信息,本次網上向社會公眾投資者發行有效申購數量為103,290,398,770張,網上中籤率為0.0006917487%,配號總數為10,329,039,877個,起訖號碼為000000000001-010329039877。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.